TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 173 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2021. The put-call ratio across all filers is 4.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $151,422,000 | +179.3% | 2,012,250 | -0.3% | 2.74% | +212.2% |
| Q1 2022 | $54,209,000 | -46.0% | 2,018,950 | -4.2% | 0.88% | -32.0% |
| Q4 2021 | $100,478,000 | -35.9% | 2,106,450 | -10.8% | 1.29% | -25.1% |
| Q3 2021 | $156,863,000 | -14.9% | 2,361,327 | 0.0% | 1.72% | -7.5% |
| Q2 2021 | $184,231,000 | -17.5% | 2,361,327 | 0.0% | 1.86% | -10.8% |
| Q1 2021 | $223,358,000 | -33.2% | 2,361,327 | -14.0% | 2.09% | -28.7% |
| Q4 2020 | $334,518,000 | +39.5% | 2,745,327 | 0.0% | 2.93% | -2.9% |
| Q3 2020 | $239,832,000 | +35.3% | 2,745,327 | 0.0% | 3.01% | +20.8% |
| Q2 2020 | $177,321,000 | +44.6% | 2,745,327 | 0.0% | 2.50% | +21.2% |
| Q1 2020 | $122,606,000 | -28.3% | 2,745,327 | 0.0% | 2.06% | -15.6% |
| Q4 2019 | $171,006,000 | +65.7% | 2,745,327 | 0.0% | 2.44% | +24.6% |
| Q3 2019 | $103,224,000 | -1.2% | 2,745,327 | +6.9% | 1.96% | +21.1% |
| Q2 2019 | $104,499,000 | – | 2,567,550 | – | 1.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |